Anthropic brings in Novartis CEO Vas Narasimhan — and that’s a bigger deal than it looks

Anthropic just made a board appointment that tells you a lot about where they think AI is heading. Vas Narasimhan, the CEO of Novartis and a physician-scientist by training, is joining their Board of Directors. He was appointed by the Anthropic Long-Term Benefit Trust, not by shareholders — and that distinction matters.

Let me explain why this is interesting beyond the usual “big name joins board” announcement.

The Long-Term Benefit Trust is this independent body with no financial stake in Anthropic. Its whole job is to keep the company honest about balancing profit with its public benefit mission. With Narasimhan’s appointment, Trust-appointed directors now hold a majority on the board. That’s a structural shift worth paying attention to.

Narasimhan isn’t just another CEO. He’s overseen the development and approval of more than 35 novel medicines at Novartis, operating in one of the most heavily regulated industries on the planet. As Daniela Amodei put it, “Getting powerful new technology to people safely and at scale is what we think about every day at Anthropic. Vas has been doing exactly that for years.” She’s not wrong.

Healthcare is one of those domains where AI’s potential is massive but the stakes are equally high. You don’t want your diagnostic model going rogue any more than you want a drug with unknown side effects hitting the market. Narasimhan has spent his career navigating that tension — pushing breakthrough science while managing regulatory risk. That’s exactly the kind of experience Anthropic needs if they’re serious about deploying AI in medicine.

Early in his career, Narasimhan worked on HIV/AIDS, malaria, and tuberculosis programs in India, Africa, and South America. He’s an elected member of the US National Academy of Medicine and sits on the Council on Foreign Relations. This isn’t someone who just shows up for board meetings; he has real operational depth in global health.

The timing makes sense too. We’re seeing AI move from chatbots to clinical decision support, drug discovery, and personalized medicine. Anthropic wants to be in that game, and having someone who understands both the science and the regulatory landscape is a strategic play.

Some might question whether a pharma CEO is the right fit for an AI company. But I’d argue that’s missing the point. The hardest problems in AI deployment aren’t technical — they’re about trust, safety, and navigating complex systems. Narasimhan has been doing that for decades. Anthropic’s board now has a majority of directors who answer to a trust with no financial interest in the company. That’s rare governance structure, and it signals they’re serious about the “long-term benefit” part of their mission.

Whether it works remains to be seen, but this is one of those moves that feels genuinely thoughtful rather than performative.